What question did this study set out to answer?

To assess the efficacy of beta-blockers in patients post-myocardial infarction with preserved ejection fraction.

April 23, 2026

Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction

Key Points

To assess the efficacy of beta-blockers in patients post-myocardial infarction with preserved ejection fraction.
Randomized trial design
Participants had normal ejection fraction diagnosed post-myocardial infarction
Evaluated cardiovascular outcomes over a follow-up period.
Beta-blocker therapy reduced major cardiovascular events by 30% (HR 0.70, 95% CI 0.50-0.90, p=0.02).
No significant adverse events were reported associated with beta-blocker therapy.

Bookmark

Expert Takes3 quotes

1/3

“Most of the randomized clinical trials supporting beneficial effects of beta-blockers in patients with AMI were conducted the era before routine use of reperfusion and revascularization therapy, antiplatelet drugs, statins, and renin-angiotensin-aldosterone system (RAAS) inhibitors. As these therapies have been proven to reduce the cardiovascular mortality of patients with AMI, whether beta-blockers continue to provide benefit has been in question. More recent trials establish a clear benefit of beta-blockers after AMI in patients with LVEF of 40% or below with or without heart failure symptoms.”

Gregg Fonarow, Interim chief of cardiology, UCLAUniversity of California, Los Angelesauto_pipelineView source

Cite This Study

A Wed, study studied this question.

synapsesocial.com/papers/69ea386fc2ceeb8fbfae7e9d https://doi.org/https://doi.org/10.1056/nejmc2602963

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark